Nerve growth factor
As of the edition of 20 October 2026, Nerve growth factor is a drug: stopped in 2020; acts on NTRK1, NTRK2 and NTRK3.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2020
- Kind
- Unknown
- Registered trials
- 11, 1 stopped early
- Disease areas
- Nervous system; Inherited and neonatal; Heart and blood vessels; Bones, joints and muscles; Digestive system; Ear, nose and throat
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 1 |
| Phase 1 | 1 | 0 | 0 | 0 |
| Phase 2 | 5 | 3 | 0 | 0 |
| Phase 3 | 1 | 0 | 1 | 0 |
| Phase 4 | 3 | 1 | 1 | 0 |
| All trials | 11 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| NsGene A/S | Lead sponsor of trials | 2008 to now |